• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

    2/3/23 11:28:40 AM ET
    $ISEE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ISEE alert in real time by email
    SC 13G/A 1 IVERIC_bio_Inc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING IVERIC BIO INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 46583P102 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO: 46583P102 13G PAGE 2 OF 5 PAGES 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 6,072,809 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 6,336,836 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,336,836 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.66% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 46583P102 13G PAGE 3 OF 5 PAGES ITEM 1. (A) NAME OF ISSUER IVERIC BIO INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 1 PENN PLAZA SUITE 3520 NEW YORK NY 10119 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER ONE LINCOLN STREET BOSTON, MA 02111 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 46583P102 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO: 46583P102 13G PAGE 4 OF 5 PAGES ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS YES ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO: 46583P102 13G PAGE 5 OF 5 PAGES ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION.
    Get the next $ISEE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISEE

    DatePrice TargetRatingAnalyst
    5/1/2023Buy → Neutral
    Guggenheim
    11/10/2022$30.00 → $20.00Buy → Hold
    Jefferies
    10/17/2022Sell → Neutral
    B. Riley Securities
    9/6/2022$12.00 → $8.00Neutral → Sell
    B. Riley Securities
    8/2/2022$20.00Buy
    UBS
    6/8/2022$30.00Buy
    Guggenheim
    6/8/2022$18.00Buy
    BofA Securities
    5/12/2022$12.00Neutral
    B. Riley Securities
    More analyst ratings

    $ISEE
    Financials

    Live finance-specific insights

    See more
    • Astellas Completes Acquisition of Iveric Bio

      TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. The completion of t

      7/11/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astellas Enters into Definitive Agreement to Acquire Iveric Bio

      -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- TOKYO and PARSIPPANY, N.J., April 30, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement un

      4/30/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

      -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas' Primary Focus on "Blindness & Regeneration"- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio"))) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a w

      4/30/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/24 8:49:05 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/23 2:33:06 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

      SC 13G/A - IVERIC bio, Inc. (0001410939) (Subject)

      2/14/23 1:10:29 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    SEC Filings

    See more

    $ISEE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ISEE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 15-12G filed by IVERIC bio Inc.

      15-12G - IVERIC bio, Inc. (0001410939) (Filer)

      7/21/23 8:30:11 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by IVERIC bio Inc.

      EFFECT - IVERIC bio, Inc. (0001410939) (Filer)

      7/18/23 12:15:15 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by IVERIC bio Inc.

      25-NSE - IVERIC bio, Inc. (0001410939) (Subject)

      7/11/23 10:24:16 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio downgraded by Guggenheim

      Guggenheim downgraded IVERIC bio from Buy to Neutral

      5/1/23 7:21:51 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio downgraded by Jefferies with a new price target

      Jefferies downgraded IVERIC bio from Buy to Hold and set a new price target of $20.00 from $30.00 previously

      11/10/22 6:43:18 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio upgraded by B. Riley Securities

      B. Riley Securities upgraded IVERIC bio from Sell to Neutral

      10/17/22 1:19:22 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Astellas Completes Acquisition of Iveric Bio

      TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ:ISEE, CEO: Glenn P. Sblendorio, ", Iveric Bio", ))) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. The completion of t

      7/11/23 7:00:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on July 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 124,860 restricted stock units for shares of the Company's common stock. The restric

      7/5/23 4:05:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The inducement grants consisted of 15,745 restricted stock units for shares of the Company's common stock. The restr

      6/2/23 4:52:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for IZERVAY issued to IVERIC BIO, INC.

      Submission status for IVERIC BIO, INC.'s drug IZERVAY (ORIG-1) with active ingredient AVACINCAPTAD PEGOL has changed to 'Approval' on 08/04/2023. Application Category: NDA, Application Number: 217225, Application Classification: Type 1 - New Molecular Entity

      8/9/23 8:37:19 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Blumenkranz Mark S.

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:02:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Carroll David Francis

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:01:28 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Miller Christine Ann

      4 - IVERIC bio, Inc. (0001410939) (Issuer)

      7/13/23 2:00:53 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ISEE
    Leadership Updates

    Live Leadership Updates

    See more
    • Iveric Bio Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer

      – Highly-Recognized Operational Executive and Strategic Advisor to Biotechnology Companies with a Proven Track Record – IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Tony Gibney to Executive Vice President and Chief Business and Strategy Officer, effective December 13, 2021. Mr. Gibney is an experienced biotechnology executive and former investment banker. Mr. Gibney brings over 25 years of experience dedicated to advising biotechnology companies in the U.S. and Europe on corporate matters such as business strategy, collaboration transactions, financings, and mergers and acquisitions. As a biotechnology executive, Mr. Gibney completed multiple strategic transactions, an

      12/13/21 5:08:00 PM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iveric Bio Appoints Christopher Simms as Chief Commercial Officer

      – Former U.S. Franchise Head of Ophthalmics at Novartis Brings a Proven Track Record in Major Retinal Product Launches – IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he successfully managed commercial operations for the U.S. Ophthalmics Franchise, launching BEOUV® (brolucizumab injection) for wet age-related macular degeneration (AMD). Before Novartis, he served as marketing lead for the Genentech ophthalmology business which included creating a new brand positioning and launching a new campaign for Lucentis® (ranibizumab in

      7/19/21 7:30:00 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      NEW YORK--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on January 4, 2021, the Company granted non-statutory stock options to purchase an aggregate of 28,000 shares of the Company’s common stock to two newly hired, non-executive employees. These grants were made pursuant to the Company’s 2019 Inducement Stock Incentive Plan, were approved by the Company’s compensation committee pursuant to a delegation by the Company’s board of directors, and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The stock options h

      1/5/21 8:00:00 AM ET
      $ISEE
      Biotechnology: Pharmaceutical Preparations
      Health Care